BioAtla sinks 47% after early results for lead candidate in solid tumor

Jan. 10, 2023 12:32 PM ETBioAtla, Inc. (BCAB)BMYBy: Dulan Lokuwithana, SA News Editor

Economic Recession and Market Crash Concept


Oncology-focused biotech BioAtla, Inc. (NASDAQ:BCAB) lost ~47% to reach the lowest level in over five months after the company shared interim results from two ongoing Phase 2 studies for its lead candidate BA3011 in patients with solid tumors.

One trial

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.